Influenza

The preferential recommendation is built on research and real-world data

Multiple pharmaceutical companies are investigating the application of mRNA technology to develop vaccines that treat and prevent multiple conditions, from influenza to cancer and beyond.

Influenza is expected to make a comeback this year, and no one knows how severe it may be.

Seqirus’s FLUCELVAX® cell-based quadrivalent influenza vaccine has been approved to expand the age indication to children as young as 6 months of age by the US Food and Drug Administration.

According to new survey data from the National Foundation for Infectious Diseases, nearly 1 in 4 people at high risk for flu-related complications, such as pregnant women, did not plan to get vaccinated.

Novavax Incorporation announced on Monday that its combined flu and COVID-19 vaccine elicited working antibodies against the viruses in a preclinical study.

Although COVID-19 safety measures helped squash the number of influenza cases last season, pharmacists are revving up vaccination programs and testing.

A study highlighted at the 2021 ASCO Annual Meeting explored whether patients who received an influenza vaccine were at increased risk for immune-related adverse events from single-agent immune checkpoint inhibitors.

In a session from the PDS 2021 Virtual Super-Conference, experts discussed how POC testing capabilities enhance patient services and address antimicrobial resistance.

A recent study looked at the role of the influenza vaccine in COVID-19 susceptibility and severity

Preventive efforts, renewed interest in vaccinations drive milder flu season.

Peramivir injection (Rapivab; BioCryst) is approved for use in patients aged 6 months and older.

Baloxavir marboxil (Xofluza; Genentech) is the first single-dose influenza medicine approved for post-exposure prophylaxis.

Pharmacies are seeing an increased demand for flu vaccines in the first season that coincides with the coronavirus pandemic.

The combined landscape of flu and COVID-19 presents challenges to vaccine uptake.

Some health care providers are taking their flu immunization efforts to the road this year.

Approximately 1-third of parents who participated in a national survey said they are unlikely to have their child vaccinated against the flu amid the pandemic.

Anticipating higher demand for the flu vaccine this season, many pharmacy chains are expanding their services.

A new report illuminates the similarities and differences between COVID-19 and seasonal influenza.

A study evaluated interference between rhinovirus and influenza A virus during the 2009 pandemic.

The American Academy of Pediatrics (AAP) has issued its recommendations for the 2020-2021 influenza season.

In a partnership with top health care experts, MJH Life Sciences™ COVID-19 Coalition will host its inaugural event, "Battling Dual Threats: Flu and COVID-19 Converge" on Tuesday, September 15, at 6 p.m. EDT.

NACDS is launching a nationwide awareness campaign on the importance of getting the flu vaccine this fall.

Results of a new study on immunization rates and current barriers at Wisconsin pharmacies demonstrated that collaborating with physicians could provide significant benefits to patients.

Experts caution about safety measures to take when offering parking lot vaccines.